Keymed Biosciences swings to FY26 H1 profit of RMB 1.22 billion; revenue rises 24% to RMB 617.07 million

• Keymed Biosciences posted IFRS profit of RMB 1.22 billion, swinging from a loss, as revenue rose 24% to RMB 617.07 million.
• Product revenue more than doubled to RMB 393 million, driven by Kangyueda’s inclusion in China’s National Reimbursement Drug List from Jan. 1, 2026.
• Collaboration revenue reached RMB 224 million, mainly from a milestone payment under the AstraZeneca license for CMG901/AZD0901.
• Other income and gains climbed to RMB 1.71 billion, primarily from disposal and realization of the equity interest in Ouro Medicines.
• Cash and equivalents, time deposits, and financial and other investments increased 65% to RMB 3.24 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keymed Biosciences Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260819-12290998), on August 19, 2026, and is solely responsible for the information contained therein.